Piramal Pharma Ltd - 543635 - Board Meeting Intimation for Considering And Approving The Audited Financial Results (Standalone And Consolidated) Of The Company For Quarter And Financial Year Ended 31St March, 2026
Piramal Pharma board will hold a meeting on April 28, 2026, to approve the audited financial results for Q4 FY26 and the full financial year ended March 31, 2026. This meeting will finalize the company's financial performance for the period.
Apr 17 2026 14:04:00
Piramal Pharma Ltd - 543635 - Successful Closure Of US FDA Inspection At Piramal Pharma'S Manufacturing Facility Located At Lexington, USA
Piramal Pharma's Lexington, USA manufacturing facility successfully closed its US FDA inspection. The company received a Voluntary Action Indicated (VAI) Establishment Inspection Report, indicating a positive outcome.
Apr 13 2026 10:04:00
Piramal Pharma Ltd - 543635 - Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015- Completion Of Acquisition Of Kenalog®, A Branded Commercial Injectable Product
Piramal Pharma's subsidiary, Piramal Critical Care B.V., completed the acquisition of Kenalog® from Bristol-Myers Squibb Company. This strengthens its Complex Hospital Generics portfolio and reinforces its presence in key markets like the US, Europe, and Asia Pacific.
Apr 01 2026 16:04:00
Read More